SCHEMBL21176186

SCHEMBL21176186

CC(C(O)C(=O)NC(C)(C)c1cccc(Cl)c1)N(C=O)C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
METAP2 P50579 4/20 0.36
METAP1 P53582 1/20 0.36
USP36 Q9P275 1/20 0.36
HTT P42858 2/20 0.35
ADH1B P00325 1/20 0.35
ADH1C P00326 1/20 0.35
ADH1A P07327 1/20 0.35
HSD11B1 P28845 1/20 0.35
HSD11B2 P80365 1/20 0.35
EPHX2 P34913 1/20 0.34
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.34
SLC6A2 P23975 2/20 0.34
NPC1 O15118 1/20 0.34
CHRNA1 P02708 1/20 0.34
CHRNG P07510 1/20 0.34
ITGA5 P08648 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975185 0.83 GAA (0.37) GAAALDH1A1L3MBTL1USP36HTT
SCHEMBL19974769 0.80 USP36 (0.40) GAAALDH1A1USP36HSD11B1POLB
SCHEMBL19975335 0.79 ALDH1A1 (0.48) GAAALDH1A1L3MBTL1EPHX2MAPT
SCHEMBL19974736 0.79 HTT (0.43) GAAALDH1A1L3MBTL1METAP2METAP1
SCHEMBL11535411 0.74 MAPT (0.54) GAAHTTHSD11B1HSD11B2RAB9A
SCHEMBL19975165 0.74 USP36 (0.43) GAAALDH1A1L3MBTL1USP36POLB
SCHEMBL19975312 0.73 LMNA (0.35) GAAUSP36RAB9ASLC6A2NPC1
SCHEMBL19974716 0.71 ADH1A (0.53) ALDH1A1METAP2METAP1ADH1BADH1C
SCHEMBL19974907 0.70 KMT2A (0.43) GAAALDH1A1L3MBTL1
SCHEMBL19974956 0.69 ADH1C (0.50) ALDH1A1HTTADH1BADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C GAA 75/4885ALDH1A1 2271/4885L3MBTL1 1238/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C GAA 107/4885ALDH1A1 2673/4885L3MBTL1 1885/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C GAA 75/4885ALDH1A1 2271/4885L3MBTL1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.